Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Aims to boost speed & precision in patient care
The collaboration is designed to improve clinical outcomes, reduce procedural risks, and expand access to advanced image-guided treatments across a growing range of conditions
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Subscribe To Our Newsletter & Stay Updated